Qual é o preço para Moleculin Biotech, Inc. (MBRX)

O preço para Moleculin Biotech, Inc. (MBRX) é $0.6155

Qual é a capitalização de mercado para Moleculin Biotech, Inc. (MBRX)

A capitalização de mercado para Moleculin Biotech, Inc. (MBRX) é $3.28M

Moleculin Biotech, Inc. (MBRX) Índice P/L

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

Ano	Índice P/E	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Índice P/E

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Rácio P/E	Diferença do rácio P/E	País
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	18.38	-	BE

Empresa

Rácio P/E

Diferença do rácio P/E

País